tafamidis

Pfizer's ATTR heart disease drug needs hefty discount, says ICER draft report. What about Alnylam's Amvuttra?
Fierce Pharma
Fri, 07/19/24 - 11:36 am
Pfizer
tafamidis
ATTR-CM
ICER
drug pricing
Ahead of Alnylam's key heart disease readout, experts say Pfizer rival would be hard to displace
Fierce Pharma
Mon, 04/22/24 - 06:01 pm
Alnylam
Pfizer
Amvuttra
ATTR-CM
tafamidis
Pfizer's 'entrenched' tafamidis franchise will be tough to challenge for Alnylam, BridgeBio: analysts
Fierce Pharma
Mon, 09/18/23 - 08:01 pm
Pfizer
BridgeBio
Alnylam
FDA
clinical trials
ATTR-CM
physicians
tafamidis
Pfizer Lawsuit Seeks to Block Generic Copy of Heart Disease Blockbuster
BioSpace
Mon, 08/14/23 - 06:47 pm
Pfizer
generics
legal
Vyndamax
heart disease
patents
tafamidis
Dexcel Pharma
Pfizer takes Vyndaqel copay fight to Supreme Court, decrying 'staggeringly overbroad' anti-kickback rule
Fierce Pharma
Mon, 10/17/22 - 11:31 pm
Pfizer
Supreme Court
kickbakcs
tafamidis
copays
Vyndaqel
Pfizer argues its case in federal court for helping seniors meet drug copays
Marketwatch
Wed, 06/23/21 - 10:27 pm
Pfizer
legal
copays
Medicare
tafamidis
Pfizer's blockbuster-to-be Vyndaqel is too costly for heart patients, study suggests
Fierce Pharma
Fri, 06/19/20 - 12:10 pm
Pfizer
tafamidis
Vyndaqel
drug pricing
Pfizer's Vyndaqel franchise, buoyed by diagnoses, is poised for 'a decisive beat': analyst
Fierce Pharma
Fri, 10/18/19 - 07:45 pm
Pfizer
tafamidis
FDA
Vyndaqel
Alnylam
Ionis
ATTR amyloidosis
Can Pfizer Leap Over the Competition With This Potential Blockbuster?
Motley Fool
Wed, 05/8/19 - 10:03 am
Pfizer
Vyndamax
tafamidis
ATTR
Alnylam
Onpattro
Akcea Therapeutics
Tegsedi
Eidos Therapeutics
AG10
Insurers Brace For Pfizer's $225K Heart Drug And Whether To Pay For It
Forbes
Mon, 05/6/19 - 07:27 pm
Pfizer
tafamidis
insurers
PBMs
ATTR
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea
Xconomy
Mon, 05/6/19 - 10:54 am
FDA
Pfizer
tafamidis
Vyndaqel
Vyndamax
ATTR
Alnylam
Akcea
Pfizer prospects for tafamidis market
Biopharma Dive
Tue, 04/30/19 - 05:38 pm
Pfizer
tafamidis
transthyretin amyloid cardiomyopathy
FDA Accepts Pfizer Submissions for Review of Treatment for Rare Amyloid Related Heart Disease
CP Wire
Mon, 01/14/19 - 10:37 am
Pfizer
ATTR
transthyretin amyloid cardiomyopathy
tafamidis
FDA Accepts Pfizer Submissions for Review of Treatment for Rare Amyloid Related Heart Disease
Mon, 01/14/19 - 10:09 am
Pfizer
ATTR
transthyretin amyloid cardiomyopathy
tafamidis
6 Things Alnylam Investors Need to Know About Pfizer's Next Blockbuster Drug
Motley Fool
Tue, 08/28/18 - 10:18 am
Alnylam
Onpattro
Pfizer
ATTR amyloidosis
tafamidis
Vyndaqel
Pfizer rare heart disease drug reduces risk of death by 30 percent in study
Reuters
Mon, 08/27/18 - 11:44 am
Pfizer
tafamidis
transthyretin amyloid cardiomyopathy
Pfizer's Next Blockbuster Drug Has Big Promise. We'll Find Out Monday How Much.
Bloomberg
Thu, 08/23/18 - 11:42 am
Pfizer
tafamidis
transthyretin cardiomyopathy
clinical trials
Pfizer Receives Breakthrough Therapy Designation for Tafamidis for Rare Heart Condition
CP Wire
Wed, 05/23/18 - 11:46 am
Pfizer
tafamidis
transthyretin cardiomyopathy
Pfizer Receives Breakthrough Therapy Designation for Tafamidis for Rare Heart Condition
Wed, 05/23/18 - 09:36 am
Pfizer
transthyretin cardiomyopathy
tafamidis
Why Pfizer's Big Win Is Bad News for Alnylam and Ionis
Yahoo/Motley Fool
Mon, 04/2/18 - 03:07 pm
Pfizer
Alnylam
Ionis Pharmaceuticals
tafamidis
inotersen
Patisiran

Pages